Takeda provides update on exkivity® (mobocertinib)

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that, following discussions with the u.s. food and drug administration (fda), it will be working with the fda towards a voluntary withdrawal of exkivity® (mobocertinib) in the u.s. for adult patients with epidermal growth factor receptor (egfr) exon20 insertion mutation-positive (insertion+) locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has progressed on or after platin.
TAK Ratings Summary
TAK Quant Ranking